Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
NA
60 participants
INTERVENTIONAL
2024-04-01
2025-07-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Objectives: The present study aims to analyze the effects of acute caffeine intake on muscular strength, power, and endurance performance according to CYP1A2 polymorphism in men and women.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Caffeine, CYPA12 and Resistance Training
NCT06610123
Caffeine, Resistance Exercise and Muscle/Cerebral Oxygenation
NCT07001176
Caffeine and Resistance Training in Older Adults
NCT06618261
Reproducibility of Acute Caffeine Effect
NCT06606639
Caffeine, Resistance Exercise and EMG
NCT06606652
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
OTHER
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Genotype AA - Male - Caffeine
Caffeine
Acute caffeine intake (3 mg/kg)
Genotype AC or CC - Male - Caffeine
Caffeine
Acute caffeine intake (3 mg/kg)
Genotype AA - Male - Placebo
Placebo
Placebo (3 mg/kg maltodextrin)
Genotype AC or CC - Male - Placebo
Placebo
Placebo (3 mg/kg maltodextrin)
Genotype AA - Female - Caffeine
Caffeine
Acute caffeine intake (3 mg/kg)
Genotype AC or CC - Female - Caffeine
Caffeine
Acute caffeine intake (3 mg/kg)
Genotype AA - Female - Placebo
Placebo
Placebo (3 mg/kg maltodextrin)
Genotype AC or CC - Female - Placebo
Placebo
Placebo (3 mg/kg maltodextrin)
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Caffeine
Acute caffeine intake (3 mg/kg)
Placebo
Placebo (3 mg/kg maltodextrin)
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Body mass index (BMI) lower than 25 kg/m².
* Physically active subjects (≥150 min/week of moderate exercise).
* Healthy men and women without neurological, cardiometabolic, immunological, or physical conditions that prevent them from performing physical exercise.
* Participants capable of performing the tests.
Exclusion Criteria
* Use of drugs or other stimulants that interfere with caffeine intake and intestinal absorption during the tests and study.
* Body mass index (BMI) ≥ 25 kg/m².
* Having undergone prolonged periods of forced physical inactivity during the 6 months prior to the study.
* Performing strenuous exercise within 48 hours prior to the tests.
* Failing to replicate the same food intake on the two experimental days.
* Consuming caffeine after 6 PM on the day prior to training or testing.
18 Years
35 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University of Alcala
OTHER
iSanidad+Herbalife
UNKNOWN
Alberto Pérez-López
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Alberto Pérez-López
Principal Investigator
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Facultad de Medicina y Ciencias de la Salud. Universidad de Alcalá
Alcalá de Henares, Madrid, Spain
Facultad de Medicina y Ciencias de la Salud. Universidad de Alcalá
Alcalá de Henares, Madrid, Spain
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CEIP/2024/2/037
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.